MRNS News and Press, Marinus Pharmaceuticals Inc. From 04/15/24

Trial did not meet pre-defined stopping criteria at the interim analysis; Marinus has completed RAISE enrollment at approximately 100 patients with topline results expected summer 2024 Future development of IV ganaxolone in refractory status epilepticus to be assessed following review of ...

2024-04-04 17:29:32 ET Gainers: Candel Therapeutics ( CADL ) +38% . Grindrod Shipping  ( GRIN ) +28% . AngioDynamics ( ANGO ) +14% . Petco Health and Wellness Company ( WOOF ) +7% . Marinus Pharmaceuticals ( MRNS ) +5% . ...

2024-03-28 17:15:02 ET Oppenheimer analyst issues PERFORM recommendation for MRNS on March 28, 2024 03:28PM ET. The previous analyst recommendation was Perform. MRNS was trading at $9.04 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cur...

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to developing and commercializing innovative therapeutics to treat seizure disorders, today affirmed its commitment to defending its patent portfolio amidst an Inter Partes Review (IPR) challenge of U.S. Patent 11,...

2024-03-24 08:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-14 06:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-05 21:29:12 ET Start Time: 16:30 End Time: 17:36 Marinus Pharmaceuticals, Inc. (MRNS) Q4 2023 Earnings Conference Call March 05, 2024, 16:30 PM ET Company Participants Scott Braunstein - CEO and Chairman Christy Shafer - Chief Commercial Officer J...

2024-03-05 16:42:18 ET Gainers: Ebang International Holdings  ( EBON ) +17% . CrowdStrike Holdings ( CRWD ) +17% . Couchbase ( BASE ) +14% . SOPHiA GENETICS ( SOPH ) +6% . Expensify ( EXFY ) +5% . Losers: ODDITY Tech...

2024-03-05 16:05:56 ET More on Marinus Pharmaceuticals Marinus Pharmaceuticals: A Capital Raise Is On The Horizon Marinus Pharmaceuticals Q4 2023 Earnings Preview Marinus Pharmaceuticals sees FY23 U.S. ZTALMY revenue $19.5M-$19.7M Seeking Alpha’s Quant...

Phase 3 RAISE trial interim analysis enrollment target achieved with Data Monitoring Committee (DMC) review scheduled and topline results expected in first half of Q2 2024 Phase 3 TrustTSC trial approximately 85% enrolled with topline data now expected in first half of Q4 2024 ZTALMY &#...